Charles Schwab’s CureVac CVAC Stock Holding History

Charles Schwab’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,244	Closed	-$215K	–	3593
2021 Q4	$215K	Buy	6,244 +331	+6%	+$13.3K	﹤0.01%	3349
2021 Q3	$323K	Buy	5,913 +340	+6%	+$20.5K	﹤0.01%	3250
2021 Q2	$410K	Buy	+5,573	New	+$557K	﹤0.01%	3202

Other funds holding CVAC

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Charles Schwab's CVAC Position: Q1 2022 in Review

Charles Schwab sold out of CureVac (CVAC) in Q1 2022, closing a stake of 6,244 shares — an estimated $215K sold.

Charles Schwab first reported a position in CVAC in Q2 2021 and held it in 3 quarters. The position peaked at $410K in Q2 2021. 111 funds tracked by Wall St. Rank hold CVAC as of Q1 2022.

Charles Schwab reported no remaining CureVac position as of Q1 2022 after selling out during the quarter.
Charles Schwab sold 6,244 CureVac shares in Q1 2022, an estimated $215K.
Charles Schwab first reported a position in CureVac in Q2 2021 and held it in 3 quarters.
Charles Schwab's CureVac position peaked at $410K in Q2 2021.
111 funds tracked by Wall St. Rank held CureVac as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.